All In Biotech

Drug Trial Radar · NCT05827146

Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

Double-blinded, Placebo-controlled, Munticenter, Phase IIa Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

Last checked: Nov 19, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Oct 7, 2023

Primary completion

Jan 30, 2024

Study completion Feb 1, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D

Conditions

  • Chronic Hepatitis D Infection

Interventions

  • HepalatideDrug

    Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.

  • Hepalatide PlaceboDrug

    Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hepatitis D Virus(HDV) RNA levelTime frame: Week 4

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • The first hospital of Jilin University

    Changchun, China

  • The first affiliated hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • the National cancer center of Mongolia

    Ulaanbaatar, Mongolia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.